Results 51 to 60 of about 3,015 (158)

Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil

Brazilian Journal of Infectious Diseases, 2018
Background This study aimed to evaluate the clinical effectiveness in terms of sustained virological response and tolerability of available second generation direct-acting antivirals in Brazilian patients.
Vinicius Lins Ferreira, Helena Hiemisch Lobo Borba, Astrid Wiens, Maria Lucia Alves Pedroso, Vanessa Ferreira de Camargo Radunz, Cláudia Alexandra Pontes Ivantes, Aline Satie Oba Kuniyoshi, Roberto Pontarolo   +7 more
doaj   +3 more sources

Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure

Advances in Virology, 2020
Background and Aims. Direct-acting antivirals (DAAs) have made a revolution in hepatitis C virus (HCV) treatment with promising reduction of HCV infection and disease morbidities.
Yousry Esam-Eldin Abo-amer, Rehab Badawi, Mohamed El-Abgeegy, Heba Fadl Elsergany, Ahmed Abdelhaleem Mohamed, Sahar Mohamed Mostafa, Hatem Samir Alegaily, Shaimaa Soliman, Sally Elnawasany, Sherief Abd-Elsalam   +9 more
doaj   +1 more source

Effect of HCV eradication by DAAs on liver steatosis, carotid atherosclerosis, and associated metabolic comorbidities: A systematic review

Liver International, Volume 44, Issue 5, Page 1075-1092, May 2024.
Abstract Background and Aims The beneficial effect of Hepatitis C virus (HCV) eradication by direct antiviral agents (DAAs) on liver fibrosis is well defined. Despite this, the impact of viral eradication in both hepatic and extra‐hepatic metabolic features is underreached.
Annalisa Cespiati, Inês Coelho Rodrigues, Inês Santos, Sara Policarpo, Sofia Carvalhana, Anna Ludovica Fracanzani, Helena Cortez‐Pinto   +6 more
wiley   +1 more source

Interferon-based Simeprevir Therapy for Pediatric Patients with Chronic Hepatitis C Viral Infection

Annals of Hepatology, 2018
Interferon-based simeprevir therapy showed high efficacy and tolerability in children with genotype 1 hepatitis C virus infection. While direct-acting antivirals (DAAs) therapy are undergoing study in children, this regimen is considered an available ...
Mitsuyoshi Suzuki, Kei Minowa, Hitoshi Tajiri   +2 more
doaj   +1 more source

Portal vein thrombosis in a patient with severe hemophilia B: A challenging balanced management

Clinical Case Reports, Volume 12, Issue 2, February 2024.
Key Clinical Message The increased life expectancy in patients with hemophilia (PwH) over the last years has raised the incidence of comorbidities, including thromboembolic events. Thromboembolic events are rare in PwH and most of them occur in the presence of exogenous risk factors.
Olga Benitez‐Hidalgo, Milagros Suito Alcántara, Maria Fernanda Martinez Garcia, Desiree Campoy, Pavel Olivera, Mercedes Gironella Mesa, Juan Carlos Juarez‐Gimenez   +6 more
wiley   +1 more source

Beyond genotype‐4: Direct‐acting antiviral agents in patients with chronic hepatitis C infection from the Eastern Province of Saudi Arabia

Health Science Reports, Volume 7, Issue 1, January 2024.
Abstract Background and Aims Direct‐acting antiviral agents (DAAs) have revolutionized the treatment of patients with chronic hepatitis C virus (HCV) infection, resulting in a high sustained virologic response (SVR) rate. However, the published data from the Eastern Province of Saudi Arabia are limited to small patient groups and specific DAAs used for
Mona H. Ismail
wiley   +1 more source

The efficacy and safety of double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alfa 2b and ribavirin) treatment regimens in chronic hepatitis C patients. The experience of everyday clinical practice

Журнал инфектологии, 2016
The objective. To evaluate the efficacy, safety and tolerability of double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alfa 2b and ribavirin) treatment regimens in chronic hepatitis C patients in everyday clinical ...
N. P. Blokhina, E. A. Nurmuhametova, M. G. Rusanova, I. V. Gagarina, E. S. Mar’jamova, N. A. Kuznetsova, T. V. Mar’janovskaja, T. V. Lopatina, O. V. Kuzina, I. N. Alekseeva, E. N. Shurenkova, A. V. Devjatkin, Yu. N. Linkova, M. A. Morozova   +13 more
doaj  

Aplastic Anemia and Severe Myelosuppression with Boceprevir or Simeprevir-Containing Hepatitis C Virus Treatment

Annals of Hepatology, 2017
The addition of the new protease inhibitors (PIs) to peg-interferon (IFN) and ribavirin (RBV), approved for chronic hepatitis C, has clearly improved sustained virological response (SVR) rates although several adverse events have been reported with this ...
Alicia Senín, Teresa Broquetas, Sabela Lens, Nuria Cañete, María-Carlota Londoño, Mariana Ferraro, Xavier Forns, Antonio Salar, Jose A. Carrión   +8 more
doaj   +1 more source

Development of a rapid phenotypic test for HCV protease inhibitors with potential use in clinical decisions

Genetics and Molecular Biology
Approximately 185 million people worldwide are chronically infected with hepatitis C virus (HCV). The first-wave of approved NS3 protease inhibitors (PIs) were Telaprevir and Boceprevir, which are currently discontinued.
Luciana Santos Pessoa, Luãnna Liebscher Vidal, Emmerson C.B. da Costa, Celina Monteiro Abreu, Rodrigo Delvecchio da Cunha, Ana Luiza Chaves Valadão, André Felipe dos Santos, Amilcar Tanuri   +7 more
doaj   +1 more source

Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.

PLoS ONE, 2017
BackgroundIntracellular HCV-RNA reduction is a proposed mechanism of action of direct-acting antivirals (DAAs), alternative to hepatocytes elimination by pegylated-interferon plus ribavirin (PR).
Valeria Cento, Thi Huyen Tram Nguyen, Domenico Di Carlo, Elisa Biliotti, Laura Gianserra, Ilaria Lenci, Daniele Di Paolo, Vincenza Calvaruso, Elisabetta Teti, Maddalena Cerrone, Dante Romagnoli, Michela Melis, Elena Danieli, Barbara Menzaghi, Ennio Polilli, Massimo Siciliano, Laura Ambra Nicolini, Antonio Di Biagio, Carlo Federico Magni, Matteo Bolis, Francesco Paolo Antonucci, Velia Chiara Di Maio, Roberta Alfieri, Loredana Sarmati, Paolo Casalino, Sergio Bernardini, Valeria Micheli, Giuliano Rizzardini, Giustino Parruti, Tiziana Quirino, Massimo Puoti, Sergio Babudieri, Antonella D'Arminio Monforte, Massimo Andreoni, Antonio Craxì, Mario Angelico, Caterina Pasquazzi, Gloria Taliani, Jeremie Guedj, Carlo Federico Perno, Francesca Ceccherini-Silberstein   +40 more
doaj   +1 more source